Diagnosis and treatment of irritable bowel syndrome: State of the art

Current Gastroenterology Reports

Volumn 7, Issue 4, 2005, Pages 249-256

  Tillisch, Kirsten ^b   Chang, Lin ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; BISACODYL; CASCARA; CILANSETRON; CIMETROPIUM; DESIPRAMINE; DICYCLOVERINE; DIPHENOXYLATE; HYOSCYAMINE; LACTULOSE; LAXATIVE; LOPERAMIDE; MACROGOL; MAGNESIUM DERIVATIVE; MEBEVERINE; NEOMYCIN; OTILONIUM BROMIDE; PAROXETINE; PINAVERIUM BROMIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SORBITOL; SPASMOLYTIC AGENT; TEGASEROD; TRIMEBUTINE; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUPUNCTURE; ANXIETY DISORDER; BEHAVIOR THERAPY; BLOATING; CHINESE MEDICINE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DIET THERAPY; DISTRESS SYNDROME; DROWSINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FECES IMPACTION; HEADACHE; HUMAN; ILEUS; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; IRRITABLE COLON; ISCHEMIC COLITIS; META ANALYSIS; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TOXIC MEGACOLON; XEROSTOMIA;

EID: 24044441883     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0016-y     Document Type: Review

References (59)

1. American Gastroenterology Association: American Gastroenterological Association medical position statement: Irritable bowel syndrome. Gastroenterology 2002, 123:2105-2107.
2. Inadomi JM, Fennerty MB, Bjorkman D: Systematic review: The economic impact of irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:671-682.
3. Gralnek IM, Hays RD, Kilbourne A, et al.: The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000, 119:654-660.
4. Longstreth GF, Wilson A, Knight K, et al.: Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 2003, 98:600-607.
5. Delvaux M: Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut 2002, 51:i67-i71.
6. Silverman DH, Munakata JA, Ennes H, et al.: Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997, 112:64-72.
7. Ringel Y, Drossman DA, Turkington TG, et al.: Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. Dig Dis Sci 2003, 48:1774-1781.
8. Naliboff BD, Derbyshire SW, Munakata J, et al.: Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosom Med 2001, 63:365-375.
9. Neal KR, Barker L, Spiller RC: Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410-413.
10. Dunlop SP, Jenkins D, Neal KR, Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003, 125:1651-1659.
11. Thompson WG, Longstreth GF, Drossman DA, et al.: Functional bowel disorders and functional abdominal pain. Gut 1999, 45:II43-II47.
12. Manning AP, Thompson WG, Heaton KW, Morris AF: Towards positive diagnosis of the irritable bowel. BMJ 1978, 2:653-654.
13. Thompson WG, Dotevall G, Drossman DA, et al.: Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989, 2:92-95.
14. Spiegel BM, DeRosa VP, Gralnek IM, et al.: Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: A cost-effectiveness analysis. Gastroenterology 2004, 126:1721-1732.
15. Vanner SJ, Depew WT, Paterson WG, et al.: Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999, 94:2912-2917.
16. Tillisch K, Labus J, Naliboff B, et al.: Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am J Gastroenterol 2005, 100:896-904.
17. Drossman DA, Morris CB, Hu Y, et al.: A prospective assessment of bowel habit in irritable bowel syndrome in women: Defining an alternator. Gastroenterology 2005, 128:580-589.
18. Whitehead WE, Palsson O, Jones KR: Systematic review of the comorbidity of irritable bowel syndrome with other disorders: What are the causes and implications? Gastroenterology 2002, 122:1140-1156.
19. Maxton DG, Morris JA, Whorwell PJ: Ranking of symptoms by patients with the irritable bowel syndrome. BMJ 1989, 299:1138.
20. Levy RL, Von Korff M, Whitehead WE, et al.: Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001, 96:3122-3129.
21. Spiegel BM, Gralnek IM, Bolus R, et al.: Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 2004, 164:1773-1780.
22. Agreus L, Svardsudd K, Nyren O, Tibblin G: Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995, 109:671-680.
23. Sperber AD, Atzmon Y, Neumann L, et al.: Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 1999, 94:3541-3546.
24. Aaron LA, Buchwald D: A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001, 134:868-881.
25. Whitehead WE, Bosmajian L, Zonderman AB, et al.: Symptoms of psychological distress associated with irritable bowel syndrome. Gastroenterology 1988, 95:709-714.
26. Drossman DA: Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995, 123:688-697.
27. Atkinson W, Sheldon TA, Shaath N, Whorwell PJ: Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut 2004, 53:1459-1464.
28. Brandt LJ, Bjorkman D, Fennerty MB, et al.: Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002, 97:S7-S26.
29. Poynard T, Regimbeau C, Benhamou Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001, 15:355-361.
30. Sun WM, Read NW, Verlinden M: Effects of loperamide oxide on gastrointestinal transit time and anorectal function in patients with chronic diarrhoea and faecal incontinence. Scand J Gastroenterol 1997, 32:34-38.
31. Bearcroft CP, Perrett D, Farthing MJG: Postprandial plasma 5-hydroxytryptamine in diarrhea predominant irritable bowel syndrome. Gut 1998, 42:42-44.
32. Houghton LA, Atkinson W, Whitaker RP, et al.: Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003, 52:663-667.
33. El-Salhy M, Norrgard O, Spinnell S: Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand J Gastroenterol 1999, 34:1007-1011.
34. Coates MD, Mahoney CR, Linden DR, et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004, 126:1657-1664.
35. Camilleri M, Northcutt AR, Kong S, et al.: The efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomised, placebo controlled study. Lancet 2000, 355:1035-1040.
36. Camilleri M, Mayer E, Drossman D, et al.: Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149-1151.
37. Camilleri M, Chey W, Mayer E, et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant IBS. Arch Intern Med 2001, 161:1733-1740.
38. Bardhan K, Bodemar G, Geldof H, et al.: A double-blind placebo-controlled study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000, 14:23-24.
39. Chang L, Ameen VZ, Dukes GE, et al.: A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol 2005, 100:115-123.
40. Berman SM, Chang L, Suyenobu B, et al.: Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist alosetron. Gastroenterology 2002, 123:969-977.
41. Bradette M, Moennikes H, Carter F, et al.: Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study. Gastroenterology 2004, 126:A42.
42. Coremans G, Clouse RE, Carter F, et al.: Cilansetron, a novel 5-HT3 antagonist, demonstrated efficacy in males with irritable bowel syndrome with diarrhea-predominance (IBS-D). Gastroenterology 2004, 126:A643.
43. Prather CM, Camilleri M, Zinsmeister AR, et al.: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000, 118:463-468.
44. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15(10):1655-66.
45. Kellow J, Lee OY, Chang FY, et al.: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003, 52:671-676.
46. Johanson JF, Wald A, Tougas G, et al.: Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004, 2:796-805.
47. Tougas G, Snape WJ Jr, Otten MH, et al.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002, 16:1701-1708.
48. Drossman DA, Toner BB, Whitehead WE, et al.: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125:19-31.
49. Creed F, Fernandes L, Guthrie E, et al.: The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124:303-317.
50. Tabas G, Beaves M, Wang J, et al.: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: A double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99:914-920.
51. Lackner JM, Mesmer C, Morley S, et al.: Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis. J Consult Clin Psychol 2004, 72:1100-1113.
52. Gonsalkorale WM, Miller V, Afzal A, Whorwell PJ: Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003, 52:1623-1629.
53. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
54. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003, 98:412-419.
55. Pimentel M, Soffer EE, Chow EJ, et al.: Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639-2643.
56. Hills JM, Aaronson PI: The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch damp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991, 101:55-65.
57. Bensoussan A, Talley NJ, Hing M, et al.: Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998, 280:1585-1589.
58. Madisch A, Holtmann G, Plein K, Hotz J: Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004, 19:271-279.
59. Rohrbock RB, Hammer J, Vogelsang H, et al.: Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. Am J Gastroenterol 2004, 99:1990-1997.